Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opdualag and SBRT in Metastatic Uveal Melanoma
NCT05077280Phase 2Recruiting
- Sponsor
- California Pacific Medical Center Research Institute
- Start
- Sep 2021
- Primary completion
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of relatlimab in Uveal melanoma (UM), sponsored by California Pacific Medical Center Research Institute. Started Sep 2021; status: recruiting.
02
Drugs
relatlimab
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT05077280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05077280.